SRI-41315|CAS 1613509-49-1|DC Chemicals

Cas No.:	1613509-49-1
Chemical Name:	Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl-
Synonyms:	Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl-
SMILES:	N1(C)C2=C(C=CC=C2)C(=O)C2C(=O)N(C3=CC=CC=C3)C(C3CCC3)=NC1=2
Formula:	C₂₂H₁₉N₃O₂
M.Wt:	357.405164957047
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

COA

Cat. No.	Product name	Field of application
DC72875	GLPG2451	GLPG2451 (GLPG 2451) is a potent potentiator of cystic fibrosis transmembrane conductance regulator (CFTR) with EC50 of 11 nM for F508del CFTR in the YHA assay and EC50 of 18 nM in TECC assay using HBE cells from patients carrying the F508del mutation. GLPG2451 improves the gating function of the CFTR channel.
DC70796	SRI-41315	SRI-41315 is a small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion, restores CFTR expression and function, suppresses CFTR nonsense mutations.SRI-41315 induces translational readthrough by depleting eRF1 protein level and prolonging the translational pause that occurs at premature termination codons (PTCs).SRI-41315 reduced eRF1 levels in a manner dependent upon a ubiquitin-mediated proteasome degradation pathway.SRI-41315 in combination with G418 restores CFTR function in primary bronchial epithelial cells derived from a CF patient with CFTR nonsense alleles.
DC48190	Vanzacaftor	Vanzacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) for treating cystic fibrosis.
DC11678	Galicaftor	Galicaftor (ABBV-2222/GLPG-2222) is an orally bioavailable small molecule that functions as a CFTR corrector, demonstrating potential for therapeutic development in cystic fibrosis research.
DC12003	Corr4A	A small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM..